vs
Side-by-side financial comparison of Chemours Co (CC) and QuidelOrtho Corp (QDEL). Click either name above to swap in a different company.
Chemours Co is the larger business by last-quarter revenue ($1.3B vs $699.9M, roughly 1.9× QuidelOrtho Corp). Chemours Co runs the higher net margin — -3.5% vs -104.7%, a 101.2% gap on every dollar of revenue. On growth, Chemours Co posted the faster year-over-year revenue change (-2.1% vs -3.7%). Chemours Co produced more free cash flow last quarter ($92.0M vs $-94.7M). Over the past eight quarters, Chemours Co's revenue compounded faster (-1.2% CAGR vs -2.9%).
The Chemours Company is an American chemical company that was founded in July 2015 as a spin-off from DuPont. It has its corporate headquarters in Wilmington, Delaware, United States. Chemours is the manufacturer of Teflon, the brand name of polytetrafluoroethylene (PTFE), known for its anti-stick properties. It also produces titanium dioxide and refrigerant gases.
QuidelOrtho Corporation is an American manufacturer of diagnostic healthcare products that are sold worldwide.
CC vs QDEL — Head-to-Head
Income Statement — Q4 FY2025 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $1.3B | $699.9M |
| Net Profit | $-47.0M | $-733.0M |
| Gross Margin | 11.7% | — |
| Operating Margin | — | -100.7% |
| Net Margin | -3.5% | -104.7% |
| Revenue YoY | -2.1% | -3.7% |
| Net Profit YoY | -261.5% | -3583.4% |
| EPS (diluted) | $-0.32 | $-10.78 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $1.3B | — | ||
| Q3 25 | $1.5B | $699.9M | ||
| Q2 25 | $1.6B | $613.9M | ||
| Q1 25 | $1.4B | $692.8M | ||
| Q4 24 | $1.4B | $707.8M | ||
| Q3 24 | $1.5B | $727.1M | ||
| Q2 24 | $1.6B | $637.0M | ||
| Q1 24 | $1.4B | $711.0M |
| Q4 25 | $-47.0M | — | ||
| Q3 25 | $46.0M | $-733.0M | ||
| Q2 25 | $-380.0M | $-255.4M | ||
| Q1 25 | $-5.0M | $-12.7M | ||
| Q4 24 | $-13.0M | $-178.4M | ||
| Q3 24 | $-32.0M | $-19.9M | ||
| Q2 24 | $60.0M | $-147.7M | ||
| Q1 24 | $54.0M | $-1.7B |
| Q4 25 | 11.7% | — | ||
| Q3 25 | 15.6% | — | ||
| Q2 25 | 17.2% | — | ||
| Q1 25 | 17.3% | — | ||
| Q4 24 | 19.4% | — | ||
| Q3 24 | 19.0% | — | ||
| Q2 24 | 19.8% | — | ||
| Q1 24 | 20.9% | — |
| Q4 25 | — | — | ||
| Q3 25 | 2.5% | -100.7% | ||
| Q2 25 | -15.4% | -29.4% | ||
| Q1 25 | — | 4.7% | ||
| Q4 24 | -0.1% | -14.2% | ||
| Q3 24 | -2.1% | 2.1% | ||
| Q2 24 | 4.4% | -18.4% | ||
| Q1 24 | 5.1% | -247.3% |
| Q4 25 | -3.5% | — | ||
| Q3 25 | 3.1% | -104.7% | ||
| Q2 25 | -23.5% | -41.6% | ||
| Q1 25 | -0.4% | -1.8% | ||
| Q4 24 | -1.0% | -25.2% | ||
| Q3 24 | -2.1% | -2.7% | ||
| Q2 24 | 3.9% | -23.2% | ||
| Q1 24 | 4.0% | -239.9% |
| Q4 25 | $-0.32 | — | ||
| Q3 25 | $0.31 | $-10.78 | ||
| Q2 25 | $-2.53 | $-3.77 | ||
| Q1 25 | $-0.03 | $-0.19 | ||
| Q4 24 | $-0.07 | $-2.54 | ||
| Q3 24 | $-0.22 | $-0.30 | ||
| Q2 24 | $0.39 | $-2.20 | ||
| Q1 24 | $0.36 | $-25.50 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $670.0M | $98.1M |
| Total DebtLower is stronger | $4.1B | $2.5B |
| Stockholders' EquityBook value | $250.0M | $2.0B |
| Total Assets | $7.4B | $5.7B |
| Debt / EquityLower = less leverage | 16.40× | 1.23× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $670.0M | — | ||
| Q3 25 | $613.0M | $98.1M | ||
| Q2 25 | $502.0M | $151.7M | ||
| Q1 25 | $464.0M | $127.1M | ||
| Q4 24 | $713.0M | $98.3M | ||
| Q3 24 | $596.0M | $143.7M | ||
| Q2 24 | $604.0M | $107.0M | ||
| Q1 24 | $746.0M | $78.5M |
| Q4 25 | $4.1B | — | ||
| Q3 25 | $4.1B | $2.5B | ||
| Q2 25 | $4.1B | $2.1B | ||
| Q1 25 | $4.1B | $2.1B | ||
| Q4 24 | $4.1B | $2.1B | ||
| Q3 24 | $4.0B | $2.2B | ||
| Q2 24 | $4.0B | $2.2B | ||
| Q1 24 | $4.0B | $2.2B |
| Q4 25 | $250.0M | — | ||
| Q3 25 | $274.0M | $2.0B | ||
| Q2 25 | $228.0M | $2.8B | ||
| Q1 25 | $566.0M | $3.0B | ||
| Q4 24 | $571.0M | $3.0B | ||
| Q3 24 | $643.0M | $3.2B | ||
| Q2 24 | $714.0M | $3.2B | ||
| Q1 24 | $753.0M | $3.3B |
| Q4 25 | $7.4B | — | ||
| Q3 25 | $7.5B | $5.7B | ||
| Q2 25 | $7.5B | $6.4B | ||
| Q1 25 | $7.4B | $6.5B | ||
| Q4 24 | $7.5B | $6.4B | ||
| Q3 24 | $7.5B | $6.8B | ||
| Q2 24 | $7.2B | $6.7B | ||
| Q1 24 | $8.0B | $6.7B |
| Q4 25 | 16.40× | — | ||
| Q3 25 | 14.96× | 1.23× | ||
| Q2 25 | 17.99× | 0.74× | ||
| Q1 25 | 7.18× | 0.70× | ||
| Q4 24 | 7.11× | 0.72× | ||
| Q3 24 | 6.20× | 0.68× | ||
| Q2 24 | 5.53× | 0.70× | ||
| Q1 24 | 5.27× | 0.68× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $137.0M | $-45.5M |
| Free Cash FlowOCF − Capex | $92.0M | $-94.7M |
| FCF MarginFCF / Revenue | 6.9% | -13.5% |
| Capex IntensityCapex / Revenue | 3.4% | 7.0% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $51.0M | $-153.1M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $137.0M | — | ||
| Q3 25 | $146.0M | $-45.5M | ||
| Q2 25 | $93.0M | $-46.8M | ||
| Q1 25 | $-112.0M | $65.6M | ||
| Q4 24 | $138.0M | $63.7M | ||
| Q3 24 | $139.0M | $117.9M | ||
| Q2 24 | $-620.0M | $-97.9M | ||
| Q1 24 | $-290.0M | $-700.0K |
| Q4 25 | $92.0M | — | ||
| Q3 25 | $105.0M | $-94.7M | ||
| Q2 25 | $50.0M | $-84.3M | ||
| Q1 25 | $-196.0M | $9.4M | ||
| Q4 24 | $29.0M | $16.5M | ||
| Q3 24 | $63.0M | $71.4M | ||
| Q2 24 | $-693.0M | $-133.2M | ||
| Q1 24 | $-392.0M | $-66.8M |
| Q4 25 | 6.9% | — | ||
| Q3 25 | 7.0% | -13.5% | ||
| Q2 25 | 3.1% | -13.7% | ||
| Q1 25 | -14.3% | 1.4% | ||
| Q4 24 | 2.1% | 2.3% | ||
| Q3 24 | 4.2% | 9.8% | ||
| Q2 24 | -44.6% | -20.9% | ||
| Q1 24 | -28.8% | -9.4% |
| Q4 25 | 3.4% | — | ||
| Q3 25 | 2.7% | 7.0% | ||
| Q2 25 | 2.7% | 6.1% | ||
| Q1 25 | 6.1% | 8.1% | ||
| Q4 24 | 8.0% | 6.7% | ||
| Q3 24 | 5.0% | 6.4% | ||
| Q2 24 | 4.7% | 5.5% | ||
| Q1 24 | 7.5% | 9.3% |
| Q4 25 | — | — | ||
| Q3 25 | 3.17× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | -10.33× | — | ||
| Q1 24 | -5.37× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CC
| Titanium Technologies | $563.0M | 42% |
| Thermal And Specialized Solutions | $443.0M | 33% |
| Advanced Performance Materials | $312.0M | 23% |
| Other Non-Reportable Segment | $12.0M | 1% |
QDEL
| Labs | $373.8M | 53% |
| Point Of Care | $164.6M | 24% |
| Immunohematology | $142.0M | 20% |
| Donor Screening | $14.7M | 2% |
| Molecular Diagnostics | $4.8M | 1% |
| Collaborative Arrangement Transaction With Party To Collaborative Arrangement | $2.1M | 0% |
